| Detected | Trial | Change |
|---|---|---|
| 2026-07-30 | NCT07478991 Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients… |
Recruitment opened |
| 2026-07-30 | NCT07507760 Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients |
Recruitment opened |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05558319 | NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs… | Newly Diagnosed Multiple Myeloma | Recruiting |
| NCT07478991 | Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients… | Acute Myeloid Leukemia, Adult | Recruiting |
| NCT03742297 | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and… | Newly Diagnosed Multiple Myeloma | Active, Not Recruiting |
| NCT04090736 | Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute… | Leukemia, Myeloid, Acute | Active, Not Recruiting |
| Phase 2 | |||
| NCT06574126 | Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma | High Risk Smoldering Multiple Myeloma | Recruiting |
| NCT07045909 | Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed… | De Novo Multiple Myeloma | Recruiting |
| NCT06544785 | Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT07507760 | Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients | Acute Myeloid Leukemia With Gene Mutations | Recruiting |
| NCT02415413 | Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple… | Smoldering Multiple Myeloma | Active, Not Recruiting |
| NCT03589222 | SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma | Refractory Multiple Myeloma | Active, Not Recruiting |
| NCT04802356 | Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients | Multiple Myeloma | Active, Not Recruiting |
| NCT05527340 | Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in… | Multiple Myeloma | Active, Not Recruiting |
| NCT05849610 | Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk… | High-Risk de Novo Multiple Myeloma | Active, Not Recruiting |
| NCT06282978 | Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to… | Multiple Myeloma in Relapse | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05060627 | Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed… | Relapsed Multiple Myeloma | Active, Not Recruiting |
| Not specified | |||
| NCT04179929 | Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults | Acute Lymphoblastic Leukemia | Recruiting |
| NCT06175702 | Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL | Lymphoblastic Leukemia | Not Yet Recruiting |
| NCT07443592 | Treatment for Ph-negative ALL for Adults up to 65 Years | Acute Lymphoblastic Leukemia | Not Yet Recruiting |
| NCT07637526 | Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed… | Relapse Multiple Myeloma | Not Yet Recruiting |